Donepezil

Donepezil is prescribed to treat:

• Alzheimer's disease and dementia • Various related conditions in the neurological category • Associated symptoms and complications

It is an important medication that helps manage these conditions effectively.

Donepezil (Aricept) is an acetylcholinesterase inhibitor used for Alzheimer's disease and other dementias. It is the most prescribed drug in its class, and setting accurate expectations about what it can and cannot do is the most important part of using it well.

Mechanism of Action

Alzheimer's disease involves early and prominent degeneration of cholinergic neurons projecting from the basal forebrain to the cortex and hippocampus — regions central to memory and attention. The resulting acetylcholine deficit contributes to cognitive symptoms.

Donepezil reversibly inhibits acetylcholinesterase, the enzyme that breaks down acetylcholine in the synapse, increasing its availability and duration of action. This partially compensates for the deficit.

The critical point is that this is purely symptomatic. Donepezil does not affect amyloid plaques, tau pathology, or neuronal loss, and it does not slow the underlying degeneration. It makes remaining cholinergic neurons work harder, and as those neurons are lost, the drug has less to act on — which is why benefit diminishes as disease advances.

The magnitude of benefit is modest. Trials show small improvements in cognitive scores and global function, typically amounting to a delay of several months in symptom progression rather than improvement or stabilisation. For some families that is meaningful; for others it is imperceptible.

Peripheral cholinergic activity produces the side effects: nausea, vomiting, diarrhoea, anorexia, bradycardia, and increased gastric acid.

Setting Expectations

The gap between what families hope for and what donepezil delivers is the source of most disappointment, and it is avoidable.

Families frequently expect memory to improve, or at least to stop declining. Neither generally happens. A realistic account is that the drug may slow the rate of decline modestly, that any benefit is often more visible in attention, engagement, and daily function than in memory testing, and that the disease will continue to progress regardless.

Stated that way, families can judge for themselves whether continuing is worthwhile — which is the right decision to leave with them. Stated as "this will help with the memory," the inevitable continued decline is experienced as the drug failing and the diagnosis worsening simultaneously.

It is also worth being explicit that donepezil is not a substitute for the interventions that do change outcomes: managing vascular risk factors, treating hearing loss, maintaining physical activity and social engagement, ensuring sleep and mood are addressed, and planning for safety and support. The dementia warning signs article covers early recognition, and the hearing loss and dementia article covers the single largest modifiable risk factor. Our neurologic team manages diagnosis and treatment.

Clinical Use

Donepezil is used across mild, moderate, and severe Alzheimer's disease, and off-label in dementia with Lewy bodies and Parkinson's disease dementia, where cholinergic deficits are often more pronounced and response can be better than in Alzheimer's.

It is not useful in mild cognitive impairment, where trials have not shown benefit in preventing progression.

In moderate to severe disease, memantine is frequently added, acting through a different mechanism, and the combination is better tolerated than expected.

Dosing starts low and increases after several weeks, since gastrointestinal effects are dose-related and largely occur at initiation. Evening dosing is conventional, though vivid dreams and insomnia sometimes prompt a switch to morning.

Deprescribing deserves as much consideration as starting. In advanced dementia, when the goals of care have shifted to comfort, continuing a drug with modest cognitive benefit and real gastrointestinal and cardiac effects is frequently not in the patient's interest. Stopping should be a deliberate, discussed decision rather than something that never comes up. The MedlinePlus donepezil entry covers prescribing detail.

Monitoring and Follow-Up

No routine laboratory monitoring is required. Weight should be tracked, since anorexia, nausea, and weight loss are common and matter in a population already at risk of poor nutrition.

Heart rate should be checked, because donepezil causes bradycardia through vagal effects and can worsen conduction disease. Syncope, falls, and pacemaker placement have all been associated with cholinesterase inhibitors, and a patient who begins falling after starting one deserves a pulse check rather than an assumption that the dementia is progressing.

Cognitive and functional assessment at intervals guides whether to continue. Caregiver burden should be assessed as a matter of routine, since it predicts institutionalisation more strongly than the patient's cognitive score does.

Anticholinergic medications directly oppose donepezil and are common in this population — bladder antimuscarinics such as oxybutynin, first-generation antihistamines, tricyclics, and cyclobenzaprine. Prescribing a cholinesterase inhibitor while continuing an anticholinergic is a genuinely self-defeating combination and is common enough to look for specifically.

The newer anti-amyloid antibodies are a separate category and the distinction matters when families ask about them. Those agents target the underlying pathology rather than the symptoms, are given by infusion, require specialist supervision and MRI monitoring for brain swelling and microhaemorrhage, and are restricted to early disease with confirmed amyloid. They are not replacements for donepezil, are not appropriate for most patients with established dementia, and their clinical benefit remains debated. The Alzheimer's Association treatment resource sets out what is currently available and for whom.

Special Populations

In older adults — essentially the whole treated population — bradycardia, falls, and weight loss are the main concerns, and reviewing the full medication list for anticholinergic burden is often more valuable than adding donepezil.

Donepezil warrants caution in significant bradycardia, sick sinus syndrome, and conduction disease, in peptic ulcer disease or with concurrent NSAIDs given increased gastric acid, in asthma and COPD, and in seizure disorders. Succinylcholine effects are prolonged, which is relevant before anaesthesia.

Hepatic impairment slows clearance. Donepezil should not be stopped and restarted casually, since restarting requires re-titration from a low dose.

When to Contact Your Doctor

Report dizziness, fainting, falls, or a slow pulse, which may indicate bradycardia. Report persistent nausea, vomiting, diarrhoea, or weight loss.

Report black or tarry stools or severe abdominal pain, which may indicate gastrointestinal bleeding. Report new or worsening agitation, hallucinations, or vivid dreams. Report seizures.

If it is unclear whether the medication is helping, say so — that is a reasonable and answerable question, and a trial off the drug is a legitimate way to find out.

To review whether donepezil is providing benefit, address side effects, or discuss stopping, contact us or schedule a visit.